Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Growth Hormone
Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation.
Peptide B
Growth Hormone
FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity.
Typical vial
2 mg
Typical dose
100-300 mcg
Half-life
~30 minutes (no DAC) / 6-8 days (with DAC)
FDA status
Not FDA approved for human use.
Typical vial
2 mg
Typical dose
1000-2000 mcg
Half-life
~26 minutes
FDA status
FDA approved. Egrifta (tesamorelin) approved November 2010 f…
CJC-1295 effects
Tesamorelin effects
CJC-1295 side effects
Tesamorelin side effects
CJC-1295 dosing ranges
Anti-aging and recovery (Mod GRF)
100 mcg · Once to three times daily (SubQ) · 8-12 weeks
Body composition (Mod GRF + Ipamorelin)
100-300 mcg · Two to three times daily · 8-12 weeks
CJC-1295 with DAC
1000-2000 mcg · Once or twice weekly · 8-12 weeks
Tesamorelin dosing ranges
HIV lipodystrophy (FDA approved)
2000 mcg · Once daily (SubQ) · Ongoing as prescribed
Body composition / anti-aging (off-label)
1000-2000 mcg · Once daily · 8-12 weeks
CJC-1295: Long-acting growth hormone releasing hormone analog for sustained GH and IGF-1 elevation. Typical dose 100-300 mcg. Tesamorelin: FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity. Typical dose 1000-2000 mcg. Both fall under the Growth Hormone category.
Stacking CJC-1295 with Tesamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
CJC-1295 is typically dosed: Once to three times daily (SubQ) for Anti-aging and recovery (Mod GRF); Two to three times daily for Body composition (Mod GRF + Ipamorelin); Once or twice weekly for CJC-1295 with DAC. Tesamorelin is typically dosed: Once daily (SubQ) for HIV lipodystrophy (FDA approved); Once daily for Body composition / anti-aging (off-label).
CJC-1295: Not FDA approved for human use. Tesamorelin: FDA approved. Egrifta (tesamorelin) approved November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta SV (reformulated single-vial) approved 2019.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free